Osteoarthritis: RCT finds duloxetine relieves pain

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a Chinese randomized controlled trial (RCT) to evaluate pain relief in patients with osteoarthritis (OA), the depression medication duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor, provided better pain relief than placebo.

Why this matters

  • More treatment options for OA pain are needed.

Study design

  • A 13-wk randomized, placebo-controlled, blinded, multicenter trial to evaluate safety and effectiveness of duloxetine 60 mg for chronic OA pain.
  • Knee or hip OA was diagnosed with American College of Rheumatology clinical and radiographic criteria.
  • Primary outcome was pain severity by Brief Pain Inventory 24-h Average Pain score.
  • At baseline, there were 205 patients in the treatment group and 202 in placebo group.
  • Funding: Eli Lilly and Company.

Key results

  • The treatment group reported less pain; the least-squares mean change from baseline to endpoint was −2.23 for duloxetine and −1.73 for placebo (P=.001).
  • Adverse events resulted in 9.0% discontinuing duloxetine treatment, compared with 4.5% discontinuation in the control group (P=.109).

Limitations

  • Short study duration.